[{"notes_id":"1_286","category":"3","subcategory":"1","title":"Thiazolidinediones","body":"Thiazolidinediones are a class of agents used in the treatment of type 2 diabetes mellitus. They are <span class=\"concept\" data-cid=\"612\">agonists to the PPAR-gamma receptor and reduce peripheral insulin resistance<\/span>. Rosiglitazone was withdrawn in 2010 following concerns about the cardiovascular side-effect profile.<br \/><br \/>The PPAR-gamma receptor is an intracellular nuclear receptor. It's natural ligands are free fatty acids and it is thought to control adipocyte differentiation and function.<br \/><br \/>Adverse effects<br \/><ul><li><span class=\"concept\" data-cid=\"7411\">weight gain<\/span><\/li><li><span class=\"concept\" data-cid=\"7412\">liver impairment<\/span>: monitor LFTs<\/li><li><span class=\"concept\" data-cid=\"7413\">fluid retention<\/span> - therefore contraindicated in <span class=\"concept\" data-cid=\"7414\">heart failure<\/span>. The risk of fluid retention is increased if the patient also takes insulin<\/li><li>recent studies have indicated an <span class=\"concept\" data-cid=\"4963\">increased risk of fractures<\/span><\/li><li><span class=\"concept\" data-cid=\"4964\">bladder cancer<\/span>: recent studies have shown an increased risk of bladder cancer in patients taking pioglitazone (hazard ratio 2.64)<\/li><\/ul>","notes_hash":"c624181981dcc2b97e2bdb6ff538bc83","knowledge_graph_node_id_link":10869,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_311\" data-linkid=\"311\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_311\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">13<\/span><button type=\"button\" style=\"\" id=\"link_dislike_311\" data-linkid=\"311\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_311\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">4<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/Recommendations\">2022 Type 2 diabetes guidelines<\/a><\/td><\/tr><\/table>","media":"","concepts_for_notes":{"612":{"concept_text":"Glitazones are agonists of PPAR-gamma receptors, reducing peripheral insulin resistance","concept_percentile":"4"},"4963":{"concept_text":"Thiazolidinediones are associated with an increased risk of osteoporosis and consequently fractures","concept_percentile":"15"},"4964":{"concept_text":"Thiazolidinediones are associated with an increased risk of bladder cancer","concept_percentile":"9"},"7411":{"concept_text":"Pioglitazone may cause weight gain","concept_percentile":"28"},"7412":{"concept_text":"Pioglitazone may cause hepatotoxicity","concept_percentile":"10"},"7413":{"concept_text":"Pioglitazone may cause fluid retention","concept_percentile":"49"},"7414":{"concept_text":"Pioglitazone - contraindicated by: heart failure","concept_percentile":"47"}},"category_name":"Endocrinology \/ Metabolic","subcategory_name":"Endocrinology","comment_count":1},"",[]]